Navigation Links
Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 14th Annual BIO CEO & Investor Conference in New York.   

The live presentation takes place on Monday, February 13 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2011 Results
2. Neurocrine Biosciences Reports Second Quarter 2011 Results
3. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
4. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
5. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
6. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
8. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
9. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
10. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... , ... Doctors in Italy, Japan, the UK and the US have reached ... gene and its link to malignant mesothelioma. Surviving Mesothelioma has just posted the details ... now. , The studies analyzed for the new report included more than 3,447 ...
(Date:5/26/2016)... and READING, England , ... ( http://www.indegene.com ), a leading global provider of ... pharmaceutical and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ... support throughout the product lifecycle, today announced the ... of IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... features a variety of fracture-specific plating options designed to address fractures of the ... fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed of ...
Breaking Biology Technology:
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):